Eva Anette Engelhardt's most recent trade in Bio-Rad Laboratories Inc. - Ordinary Shares - Class A was a trade of 4,110 Restricted Stock Units done . Disclosure was reported to the exchange on Sept. 5, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Bio-Rad Laboratories Inc (Class A) | Eva Anette Engelhardt | EVP, President, CDG | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Sep 2025 | 4,110 | 4,110 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc (Class A) | Eva Anette Engelhardt | EVP, President, CDG | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Sep 2025 | 1,152 | 1,309 (0%) | 0% | 0 | Bio-Rad A Common Stock | |
| Bio-Rad Laboratories Inc (Class A) | Eva Anette Engelhardt | EVP, President, CDG | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Sep 2025 | 1,152 | 3,456 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc (Class A) | Eva Anette Engelhardt | EVP, President, CDG | Payment of exercise price or tax liability using portion of securities received from the company at price $ 295.43 per share. | 05 Sep 2025 | 413 | 896 (0%) | 0% | 295.4 | 122,013 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc (Class A) | Eva Anette Engelhardt | EVP, President, CDG | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2025 | 245 | 738 | - | - | Restricted Stock Units | |
| Bio-Rad Laboratories Inc (Class A) | Eva Anette Engelhardt | EVP, President, CDG | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2025 | 245 | 245 (0%) | 0% | 0 | Bio-Rad A Common Stock | |
| Bio-Rad Laboratories Inc (Class A) | Eva Anette Engelhardt | EVP, President, CDG | Payment of exercise price or tax liability using portion of securities received from the company at price $ 264.19 per share. | 25 Jul 2025 | 88 | 157 (0%) | 0% | 264.2 | 23,249 | Bio-Rad A Common Stock |
| Bio-Rad Laboratories Inc (Class A) | Eva Anette Engelhardt | EVP, President, CDG | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 2,918 | 2,918 | - | - | Non-Qualified Stock Option (right to buy) | |
| Bio-Rad Laboratories Inc (Class A) | Eva Anette Engelhardt | EVP, President, CDG | 06 Sep 2024 | 4,608 | 4,608 | - | - | Restricted Stock Units | ||
| Bio-Rad Laboratories Inc (Class A) | Eva Anette Engelhardt | EVP, President, CDG | 25 Jul 2024 | 983 | 983 | - | - | Restricted Stock Units |